Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetShares Repurchased
Ratios

BridgeBio Pharma (BBIO) Receivables - Net (2021 - 2025)

BridgeBio Pharma's Receivables - Net history spans 4 years, with the latest figure at $139.4 million for Q4 2025.

  • For Q4 2025, Receivables - Net rose 2853.07% year-over-year to $139.4 million; the TTM value through Dec 2025 reached $139.4 million, up 2853.07%, while the annual FY2025 figure was $139.4 million, 2853.07% up from the prior year.
  • Receivables - Net for Q4 2025 was $139.4 million at BridgeBio Pharma, up from $116.5 million in the prior quarter.
  • Across five years, Receivables - Net topped out at $139.4 million in Q4 2025 and bottomed at $1.2 million in Q2 2021.
  • The 4-year median for Receivables - Net is $76.9 million (2025), against an average of $65.1 million.
  • The largest annual shift saw Receivables - Net skyrocketed 169.67% in 2024 before it surged 2853.07% in 2025.
  • A 4-year view of Receivables - Net shows it stood at $1.2 million in 2021, then skyrocketed by 44.35% to $1.8 million in 2023, then surged by 169.67% to $4.7 million in 2024, then soared by 2853.07% to $139.4 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Receivables - Net are $139.4 million (Q4 2025), $116.5 million (Q3 2025), and $76.9 million (Q2 2025).